Motley Fool4d agobullish
Is Kailera Therapeutics a Buy After Its Sizzling IPO?There's a new challenger to the more established players in the weight-loss drug space.
ニュース
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
296last 24h
1472last 7d
249🟢 bullish (7d)
152🔴 bearish (7d)
143publishers
Investor's Business Daily8d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.